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ABSTRACT
Real-time signal generation methods for detection
and characterization of low-abundance mutations in
genomic DNA are powerful tools for cancer diag-
nosis and prognosis. Mutations in codon 12 of the
oncogene KRAS, for example, are frequently found
in several types of human cancers. We have
developed a novel real-time PCR technology, FLAG
(FLuorescent Amplicon Generation) and adapted it
for simultaneously (i) amplifying mutated codon
12 KRAS sequences, (ii) monitoring in real-time the
amplification and (iii) genotyping the exact nucleo-
tide alteration. FLAG utilizes the exceptionally
thermostable endonuclease PspGI for real-time
signal generation by cleavage of quenched
fluorophores from the 5’-end of the PCR products
and, concurrently, for selecting KRAS mutations
over wild type. By including peptide-nucleic-acid
probes in the reaction, simultaneous genotyping
is achieved that circumvents the requirement for
sequencing. FLAG enables high-throughput, closed-
tube KRAS mutation detection down to »0.1%
mutant-to-wild type. The assay was validated on
model systems and compared with allele-specific
PCR sequencing for screening 27 cancer speci-
mens. Diverse applications of FLAG for real-time
PCR or genotyping applications in cancer, virology
or infectious diseases are envisioned.
INTRODUCTION
Diagnostic methods for the detection of speciﬁc gene
mutations associated with diseases play an increasingly
important role for early cancer diagnosis and prognosis in
clinical practice. For example, KRAS codon 12 mutations
are a predictor of resistance to tyrosine kinase inhibitors
in lung cancer (1) and of non-response to drugs like
cetuximab in colon cancer (2). One of the ﬁrst described
methods for detection of known mutations includes
PCR-RFLP (3). Subsequently, several other approaches
for discriminating speciﬁc sequence variations were
described including hybridization with allele-speciﬁc
probes (4,5), allele-speciﬁc PCR (6,7), dye terminator
incorporation (8–12), oligonucleotide ligation (13), Flap-
Endonuclease digestion (14) isothermal ampliﬁcation
assay (15) and others, reviewed by Parsons et al. (16).
These methods can be convenient, but require an addi-
tional step for end point detection. Analytical methods
that reduce sample processing to a single-step procedure
were also developed, including nick-translation PCR (17),
hybridization with FRET probes (18), melting curves
analysis (19–22), ﬂuorogenic allele-speciﬁc PCR (23),
universal FRET reagents in a single-step Invader assay
(24), universal TaqMan probes (25) and others. However,
several of these methods cannot deal with detection of a
low concentration of mutant target in the presence of
a large excess of wild-type DNA that is often found in
clinical specimens. The excess wild-type DNA can mask
the mutant signal during the detection step of the assay.
For these reasons, mutation-selection technologies such as
PCR-clamping (26) and restriction endonuclease-mediated
selection (REMS)-PCR (27) apply a preliminary step of
selective suppression of the wild-type sequences during
PCR followed by a mutation detection step. However,
the additional detection step increases the risk for contam-
ination and false positives. Furthermore, most methods
allow the detection of the presence of a mutation but not
characterization of the exact nucleotide change that took
place, and sequencing is required as an extra step for
genotyping the mutation.
Here we describe a novel real-time PCR signal
generation technology (FLAG, FLuorescent Amplicon
Generation) that is adapted to the selective ampliﬁcation
of DNA sequences with deﬁned KRAS mutations within
a large excess of wild-type DNA, and simultaneously
monitors the ampliﬁcation in real time. In addition,
FLAG can genotype the exact nucleotide alteration, thus
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speciﬁcity and sensitivity of this new assay, and validate its
use for real-time KRAS mutation detection and geno-
typing on cell lines and clinical tumor samples.
MATERIALS AND METHODS
Sourceand extraction ofgenomic DNA
Control cell lines. Genomic DNA from cultured cell lines
SW480 (KRAS codon 12 homozygous GTT), PL45
(heterozygous GAT/GGT) and CALU 1 (heterozygous
TGT/GGT) was obtained from the American Type
Culture Collection, (Manassas, California, USA) and
extracted by the NucleoSpin
TM Tissue kit (Macherey-
Nagel, Duren, Germany).
Clinical samples. Tissue specimens from sporadic color-
ectal cancers (SCRCs) were obtained with informed
consent from previously untreated patients who under-
went surgical resection at the Istituto Nazionale per lo
Studio e la Cura dei Tumori of Milan between 1998 and
2000. Tumor specimens and its surrounding normal
mucosa were selected by an experienced pathologist
from formalin-ﬁxed, paraﬃn-embedded tissue. Genomic
DNA were extracted using QIAamp Tissue Extraction kit
(Qiagen, Hilden, Germany) in the Lab of Dr Milo
Frattini, Department of Experimental Oncology and
Unit of Experimental Molecular Pathology, Istituto
Cantonale di Patologia (Locarno, Switzerland).
Selective PNA-mediated FLAG on DNA from cell lines
withKRAS mutations andclinical samples
We designed and synthesized four PNA (peptide nucleic
acids) probes (Eurogentec, Liege, Belgium) speciﬁc for
the KRAS codon 12 mutations GTT, GAT, TGT and
GCT (PNA_1 NH2-GGACCTGTTGGCGTA-CON2H,
PNA_2 NH2-GGACCTGATGGCGTA-CON2H, PNA_3
NH2-GGACCTTGTGGCGTA-CON2H, PNA_4 NH2-G
GACCTGCTGGCGTA-CON2H, respectively). Concen-
tration of forward (GA112:/5IAbFQ/TTTCCTGGTTT/
iFluorT/AGATTTACCTCTATTGTTGGATCATAT)
and reverse (GA111: 50TTTCCTGGTTTGAATATA
AACTTGTGGTAGTTGGACCT 30) primers was
300nM (IDT Inc, Coralville, IA, USA). The forward
primer carries a C/C mismatch, which allows the creation
of a PspGI recognition site only in the presence of
wild-type templates.
In each reaction, 68ng of genomic DNA extracted
from clinical samples or from wild-type K562, mutant
SW480 (homozygous GTT/GTT), PL45 (heterozygous
GAT/GGT) and CALU1 (heterozygous TGT/GGT) cell
lines were used as a template. The reaction was performed
for 35 cycles (on DNA from cell lines) or 38 cycles
(on DNA from clinical samples) as follows: denaturation
step at 948C for 10s, primers annealing at 568C for 30s,
primers extension and PNA annealing at 728C for 60s in
a Chromo 4
TM Detector Real Time PCR machine
(MJ research, Waltham, MA, USA) or an ABI 7500
Real Time PCR System (Applied Biosystems, Foster City,
CA, USA). The reaction mix contained 0.1  BD
Titanium
TM Taq polymerase, 1  PCR buﬀer (BD
Biosciences, Franklin Lakes, NJ, USA), 200mM dNTPs,
1.5mM MgCl2 in 20ml total volume. The reaction mix was
split into six reactions, performed in parallel and
compared to each other: the ﬁrst reaction is conducted
without restriction endonuclease or PNA, while the others
are in presence of PspGI (New England Biolabs, Ipswich,
MA, USA), 0.5 or 1U/ml for analysis of DNA extracted
from cell lines and clinical samples, respectively.
The third, fourth, ﬁfth and sixth reactions contain also
one of the four diﬀerent PNA probes: 300nM PNA_1
speciﬁc for codon 12 GTT, 200nM PNA_2 speciﬁc for
codon 12 GAT, 200nM PNA_3 complementary to the
TGT mutation and 200nM PNA_4 speciﬁc for GCT
targets, respectively.
By the comparison between the six parallel reactions,
the mutant samples are detected and genotyped.
Detection and genotyping ofmutant clinical samples
by allele-specific PCR followed bysequencing
Mutations of codon 12 of the KRAS oncogene were
detected in clinical samples by allele-speciﬁc PCR, and
characterized by automatic sequencing in the laboratory
of Dr M. Frattini, Department of Experimental Oncology
and Unit of Experimental Molecular Pathology, Istituto
Cantonale di Patologia (Locarno, Switzerland).
Codon 12 sequence of the KRAS gene was examined
as follows: 200ng of genomic DNA was ampliﬁed in 30ml
of ﬁnal volume reaction with 1  PCR Buﬀer II, 1.5mM
MgCl2, 0.2mM dNTPs, 0.5mM appropriate primer and
2U of AmpliTaq Gold Polymerase (all from Applied
Biosystems, Foster City, CA, USA). PCR ampliﬁcations
were performed as follows: initial denaturation step of
968C for 3min, 45 cycles of 968C for 30s, 508C for 1min,
728C for 1min, and a ﬁnal elongation step of 728C for
4min. Samples were run on 4% polyacrylamide gels
and then puriﬁed using the Puriﬁcation Kit Qiagen
(Hilden, Germany). Puriﬁed products were sequenced in
a 3130 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA).
RESULTS
The FLAG assay
FLAG is a novel method for real-time PCR signal
generation that utilizes thermostable restriction enzymes
(Figure 1). The signal generation strategy consists of
ampliﬁcation of the gene region of interest using a speciﬁc
primer pair designed to carry an 11-base sequence-tag
at the 50-end, containing the recognition site for an
exceptionally thermostable restriction endonuclease,
PspGI. The forward primer is doubly labeled at the tag
region with a quencher and a ﬂuorophore in 50 and 30
positions, respectively. During sequence extension by the
polymerase, the sequence-tag region becomes double
stranded, resulting to recognition and cleavage by
PspGI. Separation of the ﬂuorophore and the quencher
leads to generation of ﬂuorescence signal due to loss of
quenching. The unusually thermostable PspGI [activity
half-life of 2h at 958C (28)] resists deactivation during
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generation of ﬂuorescent signal during the entire course
of PCR ampliﬁcation. As a result, the exponential
build-up of double-stranded PCR product is monitored
in real time.
The originally described REMS-PCR approach (26)
consists of using a mutagenic forward primer together
with the enzyme BstNI that suppresses ampliﬁcation of
wild-type sequences and to selectively amplify mutant
alleles. PspGI is a highly thermostable isoschizomer
of BstNI, a restriction endonuclease commonly used in
REMS protocols for selective detection of KRAS codon
12 mutation (26,29). The primer-introduced variation
creates a recognition site (50-CCTGG-30) for PspGI only
when the codon 12 sequence is wild type (GGT)
(Figure 2A). PspGI is present during the ampliﬁcation
reaction and digests newly formed amplicons, suppressing
their ampliﬁcation. On the other hand, the mutant alleles
amplify exponentially during PCR since they carry a
nucleotide variation in codon 12. Consequently, the use of
PspGI in FLAG assay enables the concurrent generation
of signal and the selective ampliﬁcation of mutant codon
12 KRAS sequences during real-time PCR.
Since identiﬁcation of speciﬁc genotypes of KRAS
codon 12 mutations is useful for disease prognosis and for
diﬀerentiation of benign from malignant tissues (30,31),
we decided to genotype mutant ampliﬁcation products
obtained via FLAG, by employing PNAs in a second
FLAG reaction (Figure 2B). PNAs are non-extendable
oligonucleotides where the ribose-phosphate backbone
is replaced by (2-aminoethyl)-glycine units linked by
amide bonds (32). These synthetic oligomers form hybrids
PNA/DNA with higher thermal stability than
DNA/DNA, but which are signiﬁcantly destabilized in
the case of a single mismatch (33). A PNA probe fully
complementary to the sequence of a speciﬁc KRAS codon
12 mutant prevents annealing and extension of the
forward primer, suppressing ampliﬁcation. In presence
of a single mismatch, PNA does not inhibit primer
hybridization, which leads to ampliﬁcation and conse-
quent ﬂuorescence signal generation. Thus, four distinct
FLAG reactions are conducted for each mutation-
containing sample, each one containing a diﬀerent PNA
probe speciﬁc for the four most common KRAS codon 12
mutations (GTT, GAT, GCT, TGT) (Figure 2B). By
observing the relative signal intensity from each of these
four reactions, the identity of the mutant sequence is
inferred, as the resulting signal is weak or non-measurable
for the mutation that is fully complementary to the
mutation of the target DNA analyzed in the presence of
PNA. In summary, in the strategy depicted in Figure 2,
the ﬁrst FLAG reaction identiﬁes and monitors in real
time the mutant KRAS DNA sequences, and if the sample
is mutated a second set of real-time FLAG assays
homogenously genotypes the exact nucleotide alteration,
thereby circumventing the need for sequencing.
As an alternative, the 5 FLAG reactions depicted in
Figure 2 can be routinely carried out in parallel, thereby
obtaining both the mutation and genotyping the informa-
tion. This results to a single-step procedure at the expense
of increasing the overall number of real-time PCR
reactions required.
Selectivity of FLAG-KRAS assay
To assess the selectivity of FLAG-KRAS assay, genomic
DNA from the homozygous GTT mutant cell line SW480
was serially diluted into wild-type KRAS codon 12 DNA
from K562 cells to obtain decreasing ratios of mutant-
to-wild type sequences. Samples where mutant alleles
represented respectively 100, 10, 1, 0.1 and 0.01% of the
total DNA were subjected to FLAG-KRAS in the
presence of PspGI. Real-time PCR signals (Figure 3,
panel A) show that mutant alleles are detectable down to
1:1000 mutant-to-wild type DNA ratio and that there is
a linear relation between the threshold cycle (Ct) and the
logarithm-dilution factor of the mutant DNA in each
sample (Figure 3, panel B).
The high level of selectivity of FLAG-KRAS is enabled
by the use of PspGI, which is much more thermostable
than the isoschizomer restriction endonuclease BstNI
commonly used in REMS protocols (13,15,34). To
demonstrate this point, we performed the FLAG-KRAS
experiment using 1U/ml PspGI or 1U/ml BstNI, in
parallel. PspGI digested the wild-type codon 12 sequences
during all 38 thermal cycles of the FLAG assay, while
BstNI lost its activity, resulting in insuﬃcient suppression
of the wild-type component of the samples analyzed, thus
producing signal indiscriminately from mutant or wild-
type samples (Figure 4A and B, respectively). For BstNI
to reach a selectivity of 1:100 mutant-to-wild type ratio
following 38 PCR cycles, an addition of 10U of BstNI
PspGI recognition and cleavage
A
B
C
Q
F
Q
F
Q
F
Q
F
Figure 1. FLAG principle for real-time PCR signal generation.
The FLAG assay utilizes a primer pair carrying a tag sequence at the
50 end that contains the recognition site for the highly thermostable
enzyme PspGI. (A) One of the primers is doubly labeled at the tag
region with a quencher Q and a ﬂuorophore F. (B) During the primer
extension, the primer tag becomes double stranded, becoming available
for recognition and cleavage by the endonuclease. (C) The digestion
leads to generation of ﬂuorescence due to loss of quenching.
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Selection of 
mutant versus
wt samples
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Figure 2. PNA-mediated FLAG –KRAS assay. FLAG-KRAS assay leads to selective ampliﬁcation of mutant codon 12 KRAS sequences during
the real-time ﬂuorescent reaction through a REMS-PCR approach. (A) a mutagenic (underlined base) primer introduces a variation that creates the
recognition site for PspGI (circle) in the wild-type codon 12 (X=C, ACC) target sequence, thereby suppressing the exponential ampliﬁcation of the
wild-type allele. The mutant alleles escape digestion and this enables their exponential ampliﬁcation. (B) to assess the exact nucleotide alteration of
the target ampliﬁed, the FLAG-KRAS assay is repeated in four parallel reactions in the presence of PNA probes (dotted lines) speciﬁc for the most
common mutations of codon 12. When the reaction is conducted in the presence of the fully complementary PNA (4), no exponential ampliﬁcation
is allowed. In presence of a mismatched PNA (1–3) the probe is destabilized and the primer can consequently anneal and extend causing an
exponential ampliﬁcation and generation of FLAG ﬂuorescent signal as explained in Figure 1.
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(Figure 4C).
FLAG-KRAS combined with PNA forgenotyping
FLAG-KRAS was combined with PNA, as described in
Figure 2, for genotype determination via suppression of
mutant alleles carrying speciﬁc mutations. To demonstrate
the principle, we performed PNA-mediated FLAG-KRAS
reactions in parallel for DNA extracted from wild-type
K562 and mutant SW480 (homozygous GTT/GTT), PL45
(heterozygous GGT/GAT) and CALU1 (heterozygous
GGT/TGT) cell lines and the PCR products were run on
an ethidium-stained agarose gel. As shown in Figure 5,
all cell lines generate PCR product in the absence of
PspGI (ﬁrst panel), while no product from K562 sample
is visible in the presence of PspGI (second panel). When
the reaction is conducted in the presence of PNA probe
speciﬁc for GTT codon 12 sequence, no ampliﬁcation
product is obtained from SW480 DNA (Figure 5, panel 3).
Similarly, no product from PL45 DNA was obtained
when PNA speciﬁc for GAT was used (Figure 5, panel 4),
and no product for CALU1 DNA was obtained when
PNA speciﬁc for TGT was used (Figure 5, panel 5).
Analysisof clinical samples by PNA-mediated
FLAG-KRAS assay
The PNA-mediated FLAG-KRAS assay was applied on
27 clinical samples from patients diagnosed with spo-
radic colorectal cancers, previously analyzed for codon 12
B
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Figure 3. Selectivity of Selective FLAG-KRAS assay on cell lines.
Genomic DNA from the homozygous GTT mutant cell line SW480 was
serially diluted into wild-type KRAS codon 12 DNA from K562 cells
to obtain decreasing ratios of mutant-to-total DNA of 1:1, 1:10, 1:100,
1:1000 and 1:10000. The ﬂuorescent signals, monitored in real time, are
distinguishable from those obtained for wild-type samples down to
1:1000 mutant-to-total DNA ratio (A). A linear change of the PCR
threshold cycle versus the logarithm concentration of the mutant DNA
was observed down to 0.1% mutant-to-total DNA ratio (B).
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Figure 4. Selectivity of FLAG-KRAS assay: PspGI versus BstNI. The
FLAG-KRAS assay was performed on genomic DNA from the
homozygous GTT mutant cell line SW480 serially diluted into wild-
type DNA from K562 cells to obtain decreasing ratios of mutant-
to-total DNA of 1:1, 1:10, 1:100, 1:1000 and 1:10000. The reaction
was performed for 38 cycles in presence of PspGI (panel A) or BstNI,
(panel B). PspGI retained its activity during 38 cycles, while BstNI lost
its activity thus enabling wild type sequences to amplify together with
mutant sequences. To reach a level of selectivity of about 1:100 mutant-
to-wild type ratio using BstNI, an addition of 10 U of enzyme every
10 cycles of reaction was needed (panel C). Panel A and Panel B show
data from three independent experiments. The error bars represent the
standard deviation values.
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(ASP-S). To simultaneously detect and genotype codon
12 sequence variations present in the clinical samples, the
PNA-mediated FLAG-KRAS reactions were performed as
described in Figure 2. Representative PNA-mediated
FLAG-KRAS data are depicted in Figure 6. A ﬂuorescent
signal is produced in each reaction performed, except for
the one containing the PNA probe fully complementary
to the KRAS mutated sequence present in the sample
(Figure 6). Samples showing a Ct<38 in the FLAG assay,
in absence of PNA were considered to be mutants since
ampliﬁcation of wild-type alleles is prevented by PspGI
cleavage. The exact nucleotide change was identiﬁed
by PNA-mediated FLAG-KRAS. In this case, Ct>38
indicates suppression of the ampliﬁcation by the PNA
probefullycomplementary totheKRASmutatedsequence
and we therefore assigned to the sample the genotype
complementary to that speciﬁc PNA. The results were
compared with those obtained by ASP-S. The two tech-
niques show 81.5% concordance (Supplementary Table 1).
Out of 27 samples tested, we identiﬁed 22 concordant
positive calls, 4 positives for FLAG-KRAS (Ct<38) that
were negative for ASP-S and a negative sample (TL140,
Ct=38.1) for FLAG-KRAS that was positive for ASP-S.
The excess positives identiﬁed via FLAG-KRAS may
potentially be a result of the high selectivity of the FLAG
method that allows the detection of four mutated samples
missed by ASP-S due to the very low-abundance KRAS
mutations. Overall, there is a satisfactory agreement
between the two independent methods.
DISCUSSION
FLAG provides a novel, simple method for real-time
signal generation during PCR that is based on the use of
the exceptionally thermophilic enzyme PspGI acting
on the formed double-stranded PCR amplicons. FLAG
does not require ﬂuorogenic probes as the Taqman or
Molecular Beacons approaches (4,5,25) since the ﬂuoro-
phores are on the PCR primers, thus providing an
alternative platform for multiplexing real-time PCR
reactions. As with other non-probe-based real-time PCR
approaches (33–36), the basic requirement for a speciﬁc
signal generation by FLAG is avoiding primer–dimer
formation, which would result in false positive calls.
We addressed this problem by designing our primers
taking advantage from accurate simulations performed by
the VisualOMP4 Software to exclude any problematic
primer pairs. Because PspGI remains active during the
entire PCR course, ﬂuorescence is generated continuously
during the reaction resulting to robust signals. A potential
limitation of FLAG is that the ampliﬁed region must not
contain PspGI sites other than those incorporated at the
50-ends of the primers. This requirement restricts the
application to amplicons that are devoid of 50-CCWGG-30
sequence strings. Given that the amplicons are short, we
found that this is not a severe limitation.
We adapted FLAG to the single-step detection and
genotyping of somatic KRAS mutations within a large
excess of wild-type sequences, starting directly from
genomic DNA. The KRAS mutation selection is enabled
by the primer-mediated formation of restriction sites that
are recognized by the same enzyme used for signal
generation, the exceptionally thermophilic PspGI. The
KRAS mutation genotyping is enabled by the novel use of
PNA probes designed to interrogate speciﬁc nucleotide
changes in a set of real-time FLAG reactions. While PNA
100bp
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Variation:
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NO endonuclease
NO PNA
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+ endonuclease
NO PNA
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Figure 5. Selective PNA-mediated FLAG on cell lines. The FLAG
assay was performed on cell lines K562 (GGT/GGT), SW480
(GTT/GTT), PL45 (GGT/GAT) and CALU1 (GGT/TGT), or in
absence of DNA target, B. Panel 1: FLAG assay without PspGI
restriction endonuclease or PNA (positive controls). An ampliﬁcation
product is produced from all the reactions performed. Panel 2: FLAG
assay in presence of PspGI to detect mutant versus wild-type samples.
The wild -type sample K562 was digested by the enzyme, while the cell
lines containing a mutation are exponentially ampliﬁed. Panels 3–5:
FLAG assay with addition of PspGI and PNA speciﬁc for GTT, GAT
or TGT. No ampliﬁcation product is obtained from wild-type sample
K562 (digested by PspGI) and from the cell lines that are suppressed
by the fully complementary PNA present in the reaction.
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Figure 6. Representative PNA-mediated FLAG-KRAS obtained from
analysis of clinical samples. Four FLAG-KRAS reactions were
performed on clinical sample TL132 in presence of diﬀerent PNA
probes, speciﬁc for GTT, GAT, TGT or GCT mutations. The assays
produced ﬂuorescent amplicons in presence of all PNA, except for the
one speciﬁc for GCT mutation. The data indicate that sample T132
contains the mutation GCT.
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KRAS alleles (37,38), the present adaptation extends
the use of PNA to the genotyping of speciﬁc nucleo-
tide changes, thus circumventing the need for di-deoxy-
sequencing. This application can either be performed in
two steps (single FLAG-KRAS reaction to determine
presence of mutation, followed by a set of four parallel
reactions for genotyping, if mutation-positive) or in a
single step of ﬁve parallel real-time PCR reactions. The
ﬁrst approach reduces the total number of reactions
performed, as the wild-type samples are not processed
for a second step. The second approach provides the
advantage of speed and a closed-tube approach since
no PCR tube needs to be opened to perform a second
reaction. The closed-tube approach used for PNA-
mediated FLAG-KRAS decreases the risk of contamina-
tion that is more elevated for alternative technologies
based on multi-step reactions (16,39–41). The selectivity
of the assay was demonstrated to be 0.1% (detection of
1 mutant sequence in presence of 999 wild-type alleles).
Current protocols based on thermophilic enzymes other
than PspGI (42) require multi-step approaches to reach
similar sensitivity (43). The high selectivity of the assay
can potentially be useful for homogenous detection and
genotyping of mutations present at low prevalence
in plasma samples. Nanogram quantities of circulating
DNA are present in the plasma of normal individuals (44),
and increased quantities circulate in patients with cancer
(45–47). Detection of mutated DNA in plasma DNA may
precede conventional cancer diagnosis (48,49) resulting
to a non-invasive tool for initial detection of malignancy
as well as an indicator of recurrence during follow-up.
Detection of speciﬁc KRAS nucleotide changes in plasma
using PNA-mediated FLAG-KRAS could contribute to
a more accurate prognosis and therapy choice in certain
cancers (24,25).
In summary, PNA-mediated FLAG-KRAS is a novel
and practical method for simultaneous selection and
genotyping of KRAS sequence alterations in clinical
samples. The technology has the speciﬁcity and the selecti-
vity required for analysis of surgical/biopsy tumor samples
and can be potentially used for identiﬁcation of KRAS
codon 12 variations in ﬂuid specimens (needle aspiration,
plasma-circulating DNA). In principle it should also be
applicable for additional somatic mutations. However,
using a mutagenic primer may also reduce the priming
eﬃciency of the PCR reaction. Therefore adaptation of
the FLAG assay to additional mutations may need sub-
stantial optimization and remains to be proven in practice.
Finally, besides KRAS mutation detection, FLAG
provides a generally applicable new method for ﬂuore-
scent signal generation in real-time PCR and could be
used for multiple additional applications (e.g. in genetic
testing, infectious diseases or virology).
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